303 related articles for article (PubMed ID: 33888083)
41. Retrospective analysis of
Guo Y; Guo N; Wang J; Wang R; Tang L
Ren Fail; 2021 Dec; 43(1):729-736. PubMed ID: 33904354
[TBL] [Abstract][Full Text] [Related]
42. Out of Africa: Complete and partial remissions as a combined outcome in patients with idiopathic membranous glomerulonephritis in Cape Town.
Ameh OI; Swanepoel CR; Aderibigbe A; Kengne AP; Okpechi IG
Nephrology (Carlton); 2016 Dec; 21(12):1010-1016. PubMed ID: 26706191
[TBL] [Abstract][Full Text] [Related]
43. Detection and clinical significance of glomerular M-type phospholipase A
Liu H; Luo W; Gong S; Ding X
Intern Med J; 2016 Nov; 46(11):1318-1322. PubMed ID: 27554390
[TBL] [Abstract][Full Text] [Related]
44. Renal Phospholipase A2 Receptor and the Clinical Features of Idiopathic Membranous Nephropathy.
Xu NX; Xie QH; Sun ZX; Wang J; Li Y; Wang L; Liu SJ; Xue J; Hao CM
Chin Med J (Engl); 2017 Apr; 130(8):892-898. PubMed ID: 28397717
[TBL] [Abstract][Full Text] [Related]
45. Long-term outcome and prognostic factors of idiopathic membranous nephropathy in the Chinese population.
Zuo K; Wu Y; Li SJ; Xu F; Zeng CH; Liu ZH
Clin Nephrol; 2013 Jun; 79(6):445-53. PubMed ID: 23458172
[TBL] [Abstract][Full Text] [Related]
46. Patient age and the prognosis of idiopathic membranous nephropathy.
Yamaguchi M; Ando M; Yamamoto R; Akiyama S; Kato S; Katsuno T; Kosugi T; Sato W; Tsuboi N; Yasuda Y; Mizuno M; Ito Y; Matsuo S; Maruyama S
PLoS One; 2014; 9(10):e110376. PubMed ID: 25330372
[TBL] [Abstract][Full Text] [Related]
47. Outcome of idiopathic membranous nephropathy using targeted stepwise immunosuppressive treatment strategy.
Aaltonen S; Honkanen E
Nephrol Dial Transplant; 2011 Sep; 26(9):2871-7. PubMed ID: 21427071
[TBL] [Abstract][Full Text] [Related]
48. Leflunomide plus oral prednisone in treatment of idiopathic membranous nephropathy: a retrospective clinical study of efficacy and safety.
Yang S; Xie L; Xue W; Yin A; Lu W
Nephrology (Carlton); 2013 Sep; 18(9):615-22. PubMed ID: 23889815
[TBL] [Abstract][Full Text] [Related]
49. Phospholipase-A2 receptor antibody, 24 hours proteinuria, and serum albumin as indicators of cyclophosphamide efficacy in idiopathic membranous nephropathy.
Xiao C; Liu Y; Zhang X; Luo L; Li X; Wang T; Tian Z; Qin X; Liu J
J Clin Lab Anal; 2020 Sep; 34(9):e23368. PubMed ID: 32449206
[TBL] [Abstract][Full Text] [Related]
50. Prognostic value of neutrophil-to-lymphocyte ratio on proteinuria remission in patients with idiopathic membranous nephropathy.
Gan W; Chen J; Zhu F; Fang X; Zeng X; Xiao W; Chen W
Int Urol Nephrol; 2024 Mar; 56(3):1185-1193. PubMed ID: 37733125
[TBL] [Abstract][Full Text] [Related]
51. [The clinical efficacy and safety of modified Ponticelli regimen for treatment of idiopathic membranous nephropathy].
Xia W; Pei H; Li S; Fu S; Tian L
Zhonghua Nei Ke Za Zhi; 2016 Mar; 55(3):181-5. PubMed ID: 26926368
[TBL] [Abstract][Full Text] [Related]
52. Idiopathic membranous nephropathy in pediatric patients: presentation, response to therapy, and long-term outcome.
Chen A; Frank R; Vento S; Crosby V; Chandra M; Gauthier B; Valderrama E; Trachtman H
BMC Nephrol; 2007 Aug; 8():11. PubMed ID: 17683621
[TBL] [Abstract][Full Text] [Related]
53. The Association Between Serum Complement 4 and Kidney Disease Progression in Idiopathic Membranous Nephropathy: A Multicenter Retrospective Cohort Study.
Liu J; Zha Y; Zhang P; He P; He L
Front Immunol; 2022; 13():896654. PubMed ID: 35707542
[TBL] [Abstract][Full Text] [Related]
54. Urinary excretion of IgG and alpha(1)-microglobulin predicts clinical course better than extent of proteinuria in membranous nephropathy.
Bazzi C; Petrini C; Rizza V; Arrigo G; Beltrame A; Pisano L; D'Amico G
Am J Kidney Dis; 2001 Aug; 38(2):240-8. PubMed ID: 11479148
[TBL] [Abstract][Full Text] [Related]
55. Does immunosuppression with prednisolone and azathioprine alter the progression of idiopathic membranous nephropathy?
Ahuja M; Goumenos D; Shortland JR; Gerakis A; Brown CB
Am J Kidney Dis; 1999 Sep; 34(3):521-9. PubMed ID: 10469864
[TBL] [Abstract][Full Text] [Related]
56. Prednisolone and azathioprine in membranous nephropathy: a 10-year follow-up study.
Goumenos DS; Ahuja M; Davlouros P; El Nahas AM; Brown CB
Clin Nephrol; 2006 May; 65(5):317-23. PubMed ID: 16724651
[TBL] [Abstract][Full Text] [Related]
57. Electron-Dense Deposition Patterns and the Outcomes of Nephrotic Idiopathic Membranous Nephropathy Treated with Tacrolimus in Chinese Adults.
Xiang X; Feng Z; Jiang Q; Huang D; Meng Z; Luo Z
Med Sci Monit; 2021 Apr; 27():e930500. PubMed ID: 33896931
[TBL] [Abstract][Full Text] [Related]
58. Rituximab in idiopathic membranous nephropathy.
Ruggenenti P; Cravedi P; Chianca A; Perna A; Ruggiero B; Gaspari F; Rambaldi A; Marasà M; Remuzzi G
J Am Soc Nephrol; 2012 Aug; 23(8):1416-25. PubMed ID: 22822077
[TBL] [Abstract][Full Text] [Related]
59. New risk score for predicting progression of membranous nephropathy.
Xiaofan H; Jing X; Chenni G; Yifan W; Xialian Y; Li L; Hong R; Wen Z; Weiming W; Xiaoxia P; Jingyuan X; Nan C
J Transl Med; 2019 Feb; 17(1):41. PubMed ID: 30736804
[TBL] [Abstract][Full Text] [Related]
60. Clinical features and treatment outcome of idiopathic membranous nephropathy in Chinese patients.
Tang S; Chan TM; Cheng IK; Lai KN
QJM; 1999 Jul; 92(7):401-6. PubMed ID: 10627890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
